Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy clinical trial (NCT05468242). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Tislelizumab compare to other treatment options available to me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy clinical trial (NCT05468242). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy clinical trial (NCT05468242). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy clinical trial (NCT05468242). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the treatment process?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy clinical trial (NCT05468242). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks associated with the procedures involved in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy clinical trial (NCT05468242). Contact the study team or your healthcare provider for specific answers.

What this study is about